



SPAFID CONNECT

Informazione Regolamentata n. 0472-33-2018	Data/Ora Ricezione 19 Ottobre 2018 09:38:53	MTA - Star
--	---	------------

Societa' : BB BIOTECH

Identificativo : 109658

Informazione
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : 2.2

Data/Ora Ricezione : 19 Ottobre 2018 09:38:53

Data/Ora Inizio : 19 Ottobre 2018 09:38:54

Diffusione presunta

Oggetto : BB Biotech enlarges its Board of Directors

Testo del comunicato

Vedi allegato.

Media release of October 19, 2018

BB Biotech enlarges its Board of Directors

BB Biotech AG will propose Dr. Thomas von Planta for election to its Board of Directors.

The Board of Directors of BB Biotech AG will propose Dr. Thomas von Planta for election to its Board of Directors as new member at the next ordinary meeting of shareholders on March 21, 2019. This would increase the number of directors on the board to four.

Dr. Thomas von Planta has been the business owner and manager of CorFinAd AG since 2006, a Zurich-based consultancy for M&A and capital market transactions. Prior to that he worked for Vontobel Group as Head Investment Banking a.i. and Head Corporate Finance and served on its Extended Executive Board. Before joining Vontobel Group, Thomas was at Goldman Sachs in the Capital Markets & Investment Banking Division. He is currently Chairman of the Board of Directors of Bellevue Group AG and will not be standing for re-election at the Annual General Meeting on March 19, 2019. Thomas von Planta also sits on the Board of Directors of Bâloise Holding AG, Basel.

“I’m very pleased that Thomas von Planta is standing for election to the Board of Directors of BB Biotech,” says Dr. Erich Hunziker, Chairman of BB Biotech. “Thomas von Planta will bring profound expertise from the financial sector to the Board of Directors. This strategic enlargement will clearly enhance the board’s current strengths.”

The three existing directors, Dr. Erich Hunziker, Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein, will stand for re-election at the coming Annual General Meeting.

For further information please contact:

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch

TE-Communications AG, Bleichstrasse 11, 9000 St. Gallen, Switzerland, Tel. +41 79 423 22 28

Thomas Egger, teg@te-communications.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech’s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Fine Comunicato n.0472-33

Numero di Pagine: 3